SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001193125-18-217923
Filing Date
2018-07-13
Accepted
2018-07-13 17:01:05
Documents
6
Period of Report
2017-12-31

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 1 TO FORM 10-K d476359d10ka.htm 10-K/A 66011
2 EX-10.16 d476359dex1016.htm EX-10.16 808765
3 EX-31.3 d476359dex313.htm EX-31.3 2839
4 EX-31.4 d476359dex314.htm EX-31.4 2841
5 GRAPHIC g476359g04j25.jpg GRAPHIC 5004
6 GRAPHIC g476359g16a42.jpg GRAPHIC 3385
  Complete submission text file 0001193125-18-217923.txt   893365
Mailing Address 151 OYSTER POINT BLVD. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address 151 OYSTER POINT BLVD. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Filer) CIK: 0001714899 (see all company filings)

IRS No.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-38311 | Film No.: 18953043
SIC: 2836 Biological Products, (No Diagnostic Substances)
Assistant Director 1